Garon EB, Hellmann MD, Costa EC, et al. Five-year long-term overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001. ASCO Annual Meeting 2019, abstract LBA9015.
Trends in overleving bij uitgezaaid melanoom: analyse 2013-2021
apr 2024 | Dermato-oncologie